Research
Hormonal
Preclinical studies show conflicting results regarding GLP-1 agonists and breast cancer progression: some show inhibition of tumor growth via apoptosis, while others show promotion of growth in aggressive Triple-Negative Breast Cancer (TNBC) cell lines.
Animal studies show mixed results: GLP-1s might slow down some breast cancers but potentially speed up aggressive types (TNBC) in a lab setting. However, large human studies have not found an increased risk of developing breast cancer in people taking these drugs. If you have a history of breast cancer, discuss your specific subtype with your doctor.
LimitedQualifiesLOW confidence
In a preclinical trial, MCF-7 cell lines were treated with different concentrations of liraglutide [93]. The researchers determined that liraglutide inhibited proliferation and stimulated the apoptosis of MCF-7 human breast cancer cells [93]. ... Liu et al. demonstrated expressions of GLP-1 receptors in human TNBC cells... and tumor cell growth increased with liraglutide injection [102].
Why this rating
Based on cell culture and mouse models; human clinical data shows no increased incidence of breast cancer.
Source
The Impact and Safety of GLP‐1 Agents and Breast Cancer
Kayla Parsons et al. · Cancer Medicine · 2025
DOI 10.1002/cam4.70932
narrative_reviewCited 7×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →